Summary In 2018, the US National Institute on Aging and the Alzheimer's Association
proposed a purely biological definition of Alzheimer's disease that relies on biomarkers …

Neurodegenerative diseases are the most common cause of dementia. Although their
underlying molecular pathologies have been identified, there is substantial heterogeneity in …

Various biomarkers are available to support the diagnosis of neurodegenerative diseases in
clinical and research settings. Among the molecular imaging biomarkers, amyloid-PET …

Abstract Introduction The Alzheimer's disease (AD) continuum begins with a long
asymptomatic or preclinical stage, during which amyloid beta (Aβ) is accumulating for more …

Abstract In 2011, the National Institute on Aging and Alzheimer's Association created
separate diagnostic recommendations for the preclinical, mild cognitive impairment, and …

Technologies for imaging the pathophysiology of Alzheimer disease (AD) now permit
studies of the relationships between the two major proteins deposited in this disease …

It is not known exactly where amyloid-β (Aβ) fibrils begin to accumulate in individuals with
Alzheimer's disease (AD). Recently, we showed that abnormal levels of Aβ42 in …

Introduction Our goal was to develop cut points for amyloid positron emission tomography
(PET), tau PET, flouro-deoxyglucose (FDG) PET, and MRI cortical thickness. Methods We …

Most neurodegenerative disorders are associated with aggregated protein deposits. In the
case of Alzheimer disease (AD), extracellular amyloid-β (Aβ) aggregates and intracellular …

Alzheimer's disease (AD) is characterized by two molecular pathologies: cerebral β-
amyloidosis in the form of β-amyloid (Aβ) plaques and tauopathy in the form of neurofibrillary …